Hubei Goto Biopharm Co Ltd banner
H

Hubei Goto Biopharm Co Ltd
SZSE:300966

Watchlist Manager
Hubei Goto Biopharm Co Ltd
SZSE:300966
Watchlist
Price: 21.15 CNY -1.76% Market Closed
Market Cap: ¥2.4B

Multiples-Based Value

The Multiples-Based Value of one Hubei Goto Biopharm Co Ltd stock under the Base Case scenario is 31.14 CNY. Compared to the current market price of 21.15 CNY, Hubei Goto Biopharm Co Ltd is Undervalued by 32%.

Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Multiples-Based Value
Base Case
31.14 CNY
Undervaluation 32%
Multiples-Based Value
Price ¥21.15
H
Worst Case
Base Case
Best Case

Multiples Across Competitors

Competitors Multiples
Hubei Goto Biopharm Co Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
CN
Hubei Goto Biopharm Co Ltd
SZSE:300966
2.4B CNY 3.9 -53.1 -159.4 -159.4
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 690 872.8 -160 127.7 -194 446.1 -192 227.3
US
Abbvie Inc
NYSE:ABBV
367.6B USD 6 87.8 14.6 20.2
US
Amgen Inc
NASDAQ:AMGN
189.2B USD 5.1 24.5 14.2 14.2
US
Gilead Sciences Inc
NASDAQ:GILD
172.5B USD 5.9 20.3 12.7 15.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
110.8B USD 9.2 28 21 22
US
Epizyme Inc
F:EPE
94.1B EUR 2 091 -533.6 -581 -565.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.2B USD 5.5 17.6 13 14.8
NL
argenx SE
XBRU:ARGX
42.2B EUR 11.9 38.2 41.3 42.1
AU
CSL Ltd
ASX:CSL
67.1B AUD 3 32.9 11.1 13.9
US
Seagen Inc
F:SGT
39.3B EUR 20.1 -61.8 -66.6 -60.1
P/S Multiple
Revenue Growth P/S to Growth
CN
H
Hubei Goto Biopharm Co Ltd
SZSE:300966
Average P/S: 3 063 003.1
3.9
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
33 690 872.8
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6
9%
0.7
US
Amgen Inc
NASDAQ:AMGN
5.1
3%
1.7
US
Gilead Sciences Inc
NASDAQ:GILD
5.9
5%
1.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
9.2
11%
0.8
US
E
Epizyme Inc
F:EPE
2 091
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.5
10%
0.6
NL
argenx SE
XBRU:ARGX
11.9
28%
0.4
AU
CSL Ltd
ASX:CSL
3
4%
0.7
US
S
Seagen Inc
F:SGT
20.1
30%
0.7
P/E Multiple
Earnings Growth PEG
CN
H
Hubei Goto Biopharm Co Ltd
SZSE:300966
Average P/E: 35.6
Negative Multiple: -53.1
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 127.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
87.8
97%
0.9
US
Amgen Inc
NASDAQ:AMGN
24.5
20%
1.2
US
Gilead Sciences Inc
NASDAQ:GILD
20.3
16%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
28
19%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -533.6 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.6
14%
1.3
NL
argenx SE
XBRU:ARGX
38.2
30%
1.3
AU
CSL Ltd
ASX:CSL
32.9
9%
3.7
US
S
Seagen Inc
F:SGT
Negative Multiple: -61.8 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
CN
H
Hubei Goto Biopharm Co Ltd
SZSE:300966
Average EV/EBITDA: 18.3
Negative Multiple: -159.4
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 446.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
14.6
12%
1.2
US
Amgen Inc
NASDAQ:AMGN
14.2
10%
1.4
US
Gilead Sciences Inc
NASDAQ:GILD
12.7
9%
1.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
21
18%
1.2
US
E
Epizyme Inc
F:EPE
Negative Multiple: -581 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
13
17%
0.8
NL
argenx SE
XBRU:ARGX
41.3
49%
0.8
AU
CSL Ltd
ASX:CSL
11.1
7%
1.6
US
S
Seagen Inc
F:SGT
Negative Multiple: -66.6 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
CN
H
Hubei Goto Biopharm Co Ltd
SZSE:300966
Average EV/EBIT: 20.4
Negative Multiple: -159.4
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -192 227.3 N/A N/A
US
Abbvie Inc
NYSE:ABBV
20.2
23%
0.9
US
Amgen Inc
NASDAQ:AMGN
14.2
3%
4.7
US
Gilead Sciences Inc
NASDAQ:GILD
15.6
13%
1.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22
17%
1.3
US
E
Epizyme Inc
F:EPE
Negative Multiple: -565.5 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
14.8
23%
0.6
NL
argenx SE
XBRU:ARGX
42.1
51%
0.8
AU
CSL Ltd
ASX:CSL
13.9
10%
1.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -60.1 N/A N/A
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett